Page:United States Statutes at Large Volume 102 Part 4.djvu/95

 PUBLIC LAW 100-607—NOV. 4, 1988 "(b)

102 STAT. 3065

NOTICE TO SECRETARY AND TO ASSISTANT SECRETARY FOR

HEALTH.—The Administrator of the Alcohol, Drug Abuse, and Mental Health Administration, the Director of the Centers for Disease Control, the Commissioner of Food and Drugs, and the Director of the National Institutes of Health, shall, respectively, transmit to the Secretary and the Assistant Secretary for Health a copy of each priority request made under this section by the agency head involved. The copy shall be transmitted on the date on which the priority request involved is made. "(c) DEFINITION OF PRIORFTY REQUEST.—For purposes of this section, the term 'priority request' means any request that— "(1) is designated as a priority request by the Administrator of the Alcohol, Drug Abuse, and Mental Health Administration, the Director of the Centers for Disease Control, the Commissioner of Food and Drugs, or the Director of the National Institutes of Health; and "(2)(A) is made to the Director of the Office of Personnel Management for the allocation of personnel to carry out activities with respect to acquired immune deficiency syndrome; or "(B) is made to the Administrator of General Services for administrative support or space in carrying out such activities. "SEC. 2304. ESTABLISHMENT OF CLINICAL RESEARCH REVIEW COMMITTEE.

42 USC 300cc-3.

"(a) IN GENERAL.—After consultation with the Commissioner of Food and Drugs, the Secretary, acting through the Director of the National Institute of Allergy and Infectious Diseases, shall establish within such Institute an advisory committee to be known as the AIDS Clinical Research Review Committee (hereafter in this section referred to as the 'Committee'). "(b) COMPOSITION.—The Committee shall be composed of physicians whose clinical practice includes a significant number of patients with acquired immune deficiency syndrome. "(c) DUTIES.—The Committee shall— "(1) advise the Director of such Institute on appropriate research activities to be undertaken with respect to clinical , treatment of such syndrome, including advice with respect to— "(A) research on drugs for preventing or minimizing the development of s3anptoms or conditions arising from infection with the etiologic sigent for such s)mdrome; and "(B) research on the effectiveness of treating such symptoms or conditions with drugs that— "(i) are not approved by the Commissioner of Food and Drugs for the purpose of treating such symptoms or conditions; and "(ii) are being utilized for such purpose by individuals infected with such etiologic agent; "(2)(A) review ongoing publicly and privately supported research on clinical treatment for acquired immune deficiency Sjoidrome, including research on drugs described in paragraph (l);and "(B) periodically issue, and make available to health care Reports. professionals, reports describing and evaluating such research. "(3) conduct studies and convene meetings for the purpose of determining the recommendations among physicians in clinical practice on clinical treatment of acquired immune deficiency

�